Degenerative disorders like gonarhrosis patients with Primary fibromyalgia every Patient treated with MRCT at our centre M06.90 M45.00 M35 L40.5
Conditions
Interventions
Group 1: patients treated with MRCT in our centre
Sponsors
Campus Kerckhoff der Justus-Liebig-Universität Gießen
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: patient, who are treated with MRCT classification criteria of disease need to be fulfilled
Exclusion criteria
Exclusion criteria: missing written study consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in pain levels measured by a numeric rating scale (0-10) before and after a 16 day MRCT period | — |
Secondary
| Measure | Time frame |
|---|---|
| Change before and after a 16 day MRCT period - functional health (FFbH, HAQ, BASFI) - disease activity (DAS28, BASDAI, WOMAC, AUSCAN, FIQ) - Cytokinlevels of IL10, TNF, IL6, IL17, IL1 Change before MRCT and 12 weeks after discharge: - functional health (FFbH, HAQ, BASFI) - disease activity (DAS28, BASDAI, WOMAC, AUSCAN, FIQ) - Cytokinlevels of IL10, TNF, IL6, IL17, IL1 Change after MRCT and 12 weeks after discharge - functional health (FFbH, HAQ, BASFI) - disease activity (DAS28, BASDAI, WOMAC, AUSCAN, FIQ) - Cytokinlevels of IL10, TNF, IL6, IL17, IL1 | — |
Countries
Germany
Contacts
Public ContactPhilipp Klemm
Campus Kerckhoff der Justus Liebig Universität Giessen, Abt. für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin
Outcome results
None listed